Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Avalere Health

    Website
    Email
    +44 20 3328 1840

    Established in 2001, Avalere Health is a purposefully built commercialization partner for the biopharmaceutical, medical technology, and wellness industries. Our team of 1,500+ experts combine their knowledge and expertise across our core disciplines—Consulting; Medical; Policy; Value, Evidence, and Access; Marketing; and Digital Experience Technology—to create the connections that make better health happen.

    We partner with our clients to navigate the complex and rapidly changing healthcare ecosystem. Together, our experts help clients connect patients with life-changing therapies, realizing the potential of strategies and solutions to accelerate innovation that improves lives.

    No. 3 Booths Park, Booths Hall, Chelford Road, Knutsford, Cheshire, WA16 8GS, United Kingdom

    Avalere Health appoints new President of Medical to lead a tech-enabled future of medical affairs

    Avalere Health appoints seasoned industry executive Effie Baoutis as President of Medical.

    Fishawack Health becomes Avalere Health, uncovering the potential in every product and the possibilities for every patient

    As a single united organization, the company seamlessly connects science and creativity, technology and data, and ability and agility to ensure patients receive life-changing innovations faster.

    Industry leader Amar Urhekar joins Fishawack Health as Chief Operating Officer to integrate interdisciplinary teams across capabilities

    As Chief Operating Officer, Amar will unite global teams to drive innovation, enhance client solutions, and accelerate growth.

    Fishawack Health appoints Chief People Officer to spearhead integration of talent and culture across geographies

    Fishawack Health welcomes Harriet Shurville to the team as Chief People Officer to spearhead integration efforts, champion diversity and inclusion, and cultivate an environment where interdisciplinary teams thrive.

    Fishawack Health deepens key capabilities and builds an integrated delivery model under new Chief Marketing and Creative Officer

    Polymath marketer Ryan Mason leads the newly expanded group, and Jeffrey D. Erb has been tapped to grow the media and analytics team as Chief Media Officer.

    Fishawack Health welcomes Mario Muredda as its new President of Marketing

    Fishawack Health (FH) ushers in a new era of data-driven omnichannel marketing with the hire of healthcare marketing veteran Mario Muredda.

    Geoff Thorne joins FH as Chief Technology Officer to drive innovation for clients

    The experienced executive will expand our cross-functional omnichannel, data and analytics, and technology offerings, developing effective solutions to meet our clients’ evolving needs.

    Data-driven policy and market access firm Avalere joins Fishawack Health

    Fishawack Health bolsters its commercialization service offering with its largest addition to date, welcoming US-based policy, market access, and transformation leader Avalere.

    Fishawack Health expands its value, evidence, and market access capabilities with the acquisition of HEOR consultancy Policy Analysis Inc. (PAI)

    Fishawack Health announces its expanded global Value, Evidence, and Access (VEA) capability for biopharmaceutical and medical technology companies, with a suite of end-to-end services spanning product lifecycle, coupled with unsurpassed...

    Fishawack Health welcomes expert-led dermatology initiative FIDE to its group

    Fishawack Health welcomes FIDE, an independent organization providing its clients with insight from clinical key opinion leaders in inflammatory dermatology

    ALL PRESS RELEASES

    Archetypes: Rethinking go-to-market expectations to drive commercial success

    In this white paper, our consultants analyze trends spanning global policy developments, rising inflation, and increasingly complex customer journeys, and reveal a new data-driven approach to archetyping that crystalizes the...

    Oncology eBook: Reducing the care gap in cancer prevention, diagnosis, and treatment

    Despite significant innovation in the oncology landscape, there is a growing care gap preventing patients accessing and benefiting from innovations in cancer treatment. In this new publication, our oncology experts...

    The challenges of reimbursement and innovative pricing for cell and gene therapies

    Our policy and market access experts at Avalere, part of Fishawack Health, share insights on the reimbursement challenges for cell and gene therapies and discuss the challenges and opportunities of...

    Digital therapeutics as a combination therapy: Maximizing asset value and therapeutic outcomes

    Digital therapeutics can increase the value of medicinal assets, driving differentiation and improving outcomes for patients. But are manufacturers prepared to capitalize on this significant untapped opportunity before the tech...

    5 ways we’re enhancing our services to support our clients in 2023

    Fishawack Health CEO Jon Koch explains the new platforms, tools, and services we’re elevating to drive innovation for our clients in 2023.

    Why it’s time to apply a payer lens to your early pipeline planning

    Value, evidence, and market access experts Jan McKendrick and Andrea Hamlin reveal why applying a payer lens early in the value assessment of pipeline assets is essential for driving commercial...

    The fast-paced future of cell and gene therapies

    In this report, we interview patients, researchers, and biopharmaceutical leaders to explore the complex landscape for the development of cell and gene therapies and share commercial recommendations from our specialist...

    Omnichannel scientific engagement and the use of archetypes to drive personalization

    Natasha Cowan, Senior Corporate Communications Manager, explores with Gary Lyons, Head of Strategy, his recent plenary session at the 18th Annual ISMPP conference that focused on how scientific communicators can...

    The promised land of gene therapy: Commercialization of novel gene-editing technology in beta-thalassemia

    With transformative treatments that leverage CRISPR technology, there are many challenges to overcome throughout the journey of development through to patient access. We interviewed a researcher at a top 20...

    Report: Reinventing product and portfolio value for the biopharmaceutical industry

    Gain practical advice on determining and communicating product and portfolio value, including why, in fast-paced and evolving markets, you need to consider the evidence requirements of a growing network of...

    ALL WHITE PAPERS

    Company Details

    - PMLiVE

    Email
    Website

     Latest Content from  Avalere Health 

    The desire for connected customer experiences unites stakeholders

    Milo Elmir, Managing Consultant, examines the trends changing the behaviors of 3 healthcare stakeholders—patients, payers, and healthcare professionals—and explores how building human-centered solutions will help biopharmaceutical and medical technology companies...

    6 critical success factors for flawless execution of a rapid first commercial launch

    Annemarie Armstrong, Executive Vice President, US Head of Client Services, shares the key considerations for launching a first commercial product, particularly on a rapid timeline.

    How to innovate and influence people in times of misinformation

    The pandemic has shown that public trust in promising new medical technologies is far from a given. Senior Writer Tom Vandyck at StoneArch, a member of Fishawack delves into the...

    Fishawack Health welcomes expert-led dermatology initiative FIDE to its group

    Fishawack Health welcomes FIDE, an independent organization providing its clients with insight from clinical key opinion leaders in inflammatory dermatology

    Rethinking immunodermatology: Patient and market insights from leading KOLs and life science leaders

    In our new publication, we speak to key opinion leaders and industry experts to uncover novel strategies for commercializing immunodermatology therapies in a crowded market landscape.

    How we’re empowering our teams to fight healthcare inequality

    Welcoming Sheena Amin-Liebman as our new Diversity and Inclusion Director. Sheena will play a vital role in creating an inspiring environment that empowers staff to better guide its clients in...

    Accelerating HTA and payer submissions: how digital connectivity is driving faster patient access

    Sotiria Papanicolaou, Chief Consulting Officer at PRMA Consulting, a member of Fishawack Health, explains how the combination of digital innovation and expert insight are removing roadblocks and speeding up the...

    Future focus: 3 tools for launching fast in the face of uncertainty

    Dan Twibell, Head of Commercial Strategy, Consulting at Fishawack Health, reveals 3 fundamental tools for lean biotechs approaching a rapid launch. He gives his advice on how to manage resources...

    Fishawack Health appoints new CEO, Jonathan Koch

    Koch will draw on his exceptional experience leading global, customer-centered organizations of scale to build a sustainable future for Fishawack Health.

    Fishawack Health appoints Elizabeth Landon in the newly created Chief People Officer role

    Elizabeth Landon brings exceptional leadership from a career supporting and scaling people-based businesses in the professional services and non-profit sectors.